Related Experiment Videos
Mutated RAS: Targeting the "Untargetable" with T Cells
Praveen D Chatani1, James C Yang2
1Surgery Branch, National Cancer Institute, NIH, Bethesda, Maryland. Praveen.Chatani@nih.gov.
Abstract:
The RAS family of proteins is at the apex of several pathways implicated in a multitude of epithelial cancers but has remained stubbornly resistant to the wave of targeted small molecules and antibodies that have revolutionized clinical oncology. KRAS, the most commonly mutated of the isoforms, represents an attractive target for treatment, given its ubiquity, central role as a driver mutation, and association with poor prognosis. This review is a comprehensive summary of the existing approaches to targeting KRAS spanning small-molecule inhibitors, cancer vaccines, and with a focus on trials in adoptive cell therapy. Here we explain how the limitations of existing drugs and nonspecific immune-based therapies are circumvented with techniques in modern immunotherapy. The successes outlined represent the most promising path to finally targeting the prototypical "undruggable" RAS oncogene family.
Insights
Targeting the RAS oncogene family, particularly KRAS, in epithelial cancers is challenging. Modern immunotherapy offers promising new strategies to overcome limitations of existing treatments for these difficult-to-treat cancers.
Area of Science:
- Oncology
- Molecular Biology
- Immunotherapy
Background:
- The RAS protein family is crucial in epithelial cancer pathways but has resisted targeted therapies.
- KRAS mutations are common, driving cancer growth and leading to poor prognoses, making it a key therapeutic target.
Purpose of the Study:
- To provide a comprehensive review of current strategies for targeting the RAS family, with a focus on KRAS.
- To highlight advancements in immunotherapy, including adoptive cell therapy, for overcoming KRAS-targeting challenges.
Main Methods:
- Review of existing literature on small-molecule inhibitors, cancer vaccines, and adoptive cell therapy for RAS-targeted treatment.
- Analysis of modern immunotherapy techniques to circumvent limitations of conventional drugs and non-specific immune therapies.
Main Results:
- Existing targeted therapies have shown limited success against the RAS family.
- Modern immunotherapy approaches demonstrate significant promise in overcoming previous treatment barriers.
Conclusions:
- Targeting the RAS oncogene family, especially KRAS, remains a critical unmet need in cancer therapy.
- Immunotherapy, particularly adoptive cell therapy, presents the most promising avenue for effectively targeting the previously "undruggable" RAS proteins.